Molecular Pathological Markers Correlated With the Recurrence Patterns of Glioma

Molecular Pathological Markers Correlated With the Recurrence Patterns of Glioma

PurposeGlioma is one of the most common tumors of the central nervous system, and many patients suffer from recurrence even after standard comprehensive treatment. However, little is known about the molecular markers that predict the recurrence patterns of glioma. This study aimed to demonstrate the...

Full description

Bibliographic Details
Main Authors:	Shunnan Ge, Yingwu Shi, Gang Zhu, Songlun Li, Yaning Cai, Peigang Ji, Jinghui Liu, Wei Guo, Li Gong, Miao Lou, Fuqiang Feng, Yuan Wang, Yulong Zhai, Yan Qu, Liang Wang
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2021-01-01
Series:	Frontiers in Oncology
Subjects:	glioma local recurrence paraventricular recurrence molecular markers O6-Methylguanine DNA methyltransferase
Online Access:	https://www.frontiersin.org/articles/10.3389/fonc.2020.565045/full

Similar Items

Behavior-Oriented Nomogram for the Stratification of Lower-Grade Gliomas to Improve Individualized Treatment
by: Ruo-Lun Wei, et al.
Published: (2020-12-01)

O-6-methylguanine-DNA methyltransferase promoter methylation can change in glioblastoma recurrence due to intratumor heterogeneity
by: Valeria Barresi, et al.
Published: (2018-01-01)

Research and application progress of MGMT promoter methylation in gliomas
by: Cui-yun SUN, et al.
Published: (2014-07-01)

Retrospective study on MGMT methylation status and its clinical significance in gliomas
by: JIANG Lin, LIU Qiying, JIA Liqing, ZHANG Jing, CHANG Heng, XUE Tian, REN Min, BAI Qianming, ZHU Xiaoli, ZHOU Xiaoyan
Published: (2023-08-01)

Prognostic genetic markers in malignant gliomas
by: Ralf Ketter, et al.
Published: (2010-12-01)

Prognostic effects of O6-Methylguanine DNA methyltransferase promoter hypermethylation in high-grade glioma patients with carmustine wafer implants
by: Mao-Yu Chen, et al.
Published: (2017-01-01)

Quantitative Analysis of the <i>MGMT</i> Methylation Status of Glioblastomas in Light of the 2021 WHO Classification
by: Levin Häni, et al.
Published: (2022-06-01)

Rare Stochastic Expression of O6-Methylguanine- DNA Methyltransferase (MGMT) in MGMT-Negative Melanoma Cells Determines Immediate Emergence of Drug-Resistant Populations upon Treatment with Temozolomide In Vitro and In Vivo
by: Thomas C. Chen, et al.
Published: (2018-09-01)

The diagnostic value of ADC histogram and direct ADC measurements for coexisting isocitrate dehydrogenase mutation and O6-methylguanine-DNA methyltransferase promoter methylation in glioma
by: Zhiyan Xie, et al.
Published: (2023-01-01)

Exploring the Mechanism of Adjuvant Treatment of Glioblastoma Using Temozolomide and Metformin
by: Shao-Wei Feng, et al.
Published: (2022-07-01)

Temozolomide is additive with cytotoxic effect of irradiation in canine glioma cell lines
by: Nina Simona Tresch, et al.
Published: (2021-11-01)

Triple combination of lomustine, temozolomide and irradiation reduces canine glioma cell survival in vitro
by: Daniel Fuchs, et al.
Published: (2023-07-01)

The Clinical Significance of O6-Methylguanine-DNA Methyltransferase Promoter Methylation Status in Adult Patients With Glioblastoma: A Meta-analysis
by: Yu-Hang Zhao, et al.
Published: (2018-03-01)

WHO grade III diffuse astrocytic glioma in a 35-year-old male
by: Rong Du, et al.
Published: (2022-01-01)

O6-methylguanine-DNA Methyltransferase Promoter Methylation in Patients with Rectal Adenocarcinoma After Chemoradiotherapy Treatment: Clinical Implications
by: Jaime A. Oliver, et al.
Published: (2019-09-01)

Recurrent glioblastoma with unmethylated MGMT promoter treated by temozolomide + bevacizumab + tumor⁃treating fields: one case report
by: YANG Bo⁃cheng, et al.
Published: (2021-11-01)

Strategy of awake surgical resection for glioma based on intraoperative functional mapping and monitoring: A case report
by: Yingwu Shi, et al.
Published: (2020-01-01)

Associations of O6-methylguanine-DNA methyltransferase promoter methylation status with age and 1p/19q codeletion status in isocitrate dehydrogenase mutation gliomas based on an Asian cohort: A narrative review
by: Xu Wang, et al.
Published: (2022-01-01)

Experimental study of selective MGMT peptides mimicking TMZ drug resistance in glioma
by: Yue Wu, et al.
Published: (2022-12-01)

Alternative temozolomide dosing regimens and novel combinations for the treatment of advanced metastatic melanoma
by: Wen-Jen Hwu, et al.
Published: (2011-12-01)

Determining methylation status of methylguanine DNA methyl transferase (MGMT) from formalin-fixed, paraffin embedded tumor tissue
by: Francine B. de Abreu, et al.
Published: (2014-01-01)

Immunotherapy for Recurrent Glioma—From Bench to Bedside
by: Yi Pu, et al.
Published: (2023-06-01)

Sonodynamic therapy for a child with recurrent brainstem Glioma: A case report
by: Qianqian Dang, et al.
Published: (2023-06-01)

Abnormal MGMT Promoter Methylation in Gastrointestinal Stromal Tumors: Genetic Susceptibility and Association with Clinical Outcome
by: Lou L, et al.
Published: (2020-10-01)

Clinical significance of histopathological features of paired recurrent gliomas: a cohort study from a single cancer center
by: Cong Li, et al.
Published: (2023-01-01)

A Novel Nomogram for Predicting the Risk of Short-Term Recurrence After Surgery in Glioma Patients
by: Tianwei Wang, et al.
Published: (2021-10-01)

Retrospective analysis to evaluate the efficacy and the safety of Bevacizumab in the treatment of recurrent malignant gliomas
by: Arsela Prelaj, et al.
Published: (2018-04-01)

Surgical and therapeutic strategy of recurrent malignant gliomas in intractable location
by: Yun⁃tao LU, et al.
Published: (2012-12-01)

A Review of the Role of Re-Irradiation in Recurrent High-Grade Glioma (HGG)
by: Maurizio Amichetti, et al.
Published: (2011-10-01)

Pineal Region Glioblastoma, a Case Report and Literature Review
by: Hayley Beacher Stowe, et al.
Published: (2017-06-01)

The prognostic impact of O 6- methylguanine DNA methyltransferase and epidermal growth factor receptor expressions on primary gliosarcoma: A clinicopathologic and immunohistochemical study of seven cases at a single institution
by: Jui-Wei Lin, et al.
Published: (2011-01-01)

Evaluation of O6-methylguanine-DNA methyltransferase enzyme expression effect on survival of patients with Grade 4 brain astrocytoma
by: Simin Hemati, et al.
Published: (2014-01-01)

Evaluation of prognostic utility of Ki-67, P53, and O-6-methylguanine-DNA methyltransferase expression in pituitary tumors
by: Chhanda Das, et al.
Published: (2019-10-01)

Prediction of the Molecular Subtype of IDH Mutation Combined with MGMT Promoter Methylation in Gliomas via Radiomics Based on Preoperative MRI
by: Yongjian Sha, et al.
Published: (2023-02-01)

Validation of MRI-Based Models to Predict MGMT Promoter Methylation in Gliomas: BraTS 2021 Radiogenomics Challenge
by: Byung-Hoon Kim, et al.
Published: (2022-10-01)

Bevacizumab in recurrent WHO grades II–III glioma
by: Soufyan Annakib, et al.
Published: (2023-07-01)

Progress of temozolomide in the treatment of recurrent high-grade gliomas
by: Jin-duo LI, et al.
Published: (2013-12-01)

Application and advance of temozolomide in the treatment of pituitary adenomas
by: Yi-guang LIN, et al.
Published: (2015-12-01)

Western Pacific ALS-PDC: a prototypical neurodegenerative disorder linked to DNA damage and aberrant proteogenesis?
by: Peter eSpencer, et al.
Published: (2012-12-01)

C8-Substituted Imidazotetrazine Analogs Overcome Temozolomide Resistance by Inducing DNA Adducts and DNA Damage
by: Zhikuan Yang, et al.
Published: (2019-06-01)